The Food and Drug Administration on Friday approved Reyataz (atazanavir), a once-daily HIV protease inhibitor developed by Bristol-Myers Squibb. The drug is the first protease inhibitor designed to be taken just once per day, significantly reducing the pill burden of HIV-positive people who often are required to take several pills several times a day. Reyataz is dosed as two 200-milligram pills taken with food. Reyataz also can be taken at the same time as other anti-HIV medications. Studies also have shown that Reyataz does not significantly boost blood-based lipid levels, a problem linked with other protease inhibitors. However, up to 24% of patients taking Reyataz can experience jaundice, resulting in a yellowing of the eyes or the skin. Studies have shown that the side effect does not appear to cause liver damage and that the jaundice dissipates when the drug is stopped. Bristol-Myers Squibb officials say the drug will be available in July. Reyataz's price has not yet been announced by the company.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














